EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”)

Umidakhon Makhmudova, Beasat Samadifar, Aurel Maloku, Pellumb Haxhikadrija, Jens-Arndt Geiling, Robert Römer, Bernward Lauer, Sven Möbius-Winkler, Sylvia Otto, P Christian Schulze, Oliver Weingärtner

Clinical Research in Cardiology · 2023-09 · 112 (9) · 1212-1219

DOI: 10.1007/s00392-022-02147-3 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Research in Cardiology, online erschienen am 05.01.2023. Verfasst von Umidakhon Makhmudova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. Hauptthemen laut MEDLINE: Anticholesteremic Agents, ST Elevation Myocardial Infarction, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Jena.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Currently, less than 20% of patients at very high-risk achieve ESC/EAS dyslipidemia guideline-recommended LDL-C target levels in Europe. “Jena auf Ziel—JaZ” is a prospective cohort study in which early combination therapy with atorvastatin 80 mg and ezetimibe 10 mg was initiated on admission in patients with ST-elevation myocardial infarction (STEMI) and lipid-lowering therapy was escalated during follow-up with bempedoic acid and PCSK9 inhibitors to achieve recommended LDL-C targets in all patients. Moreover, we evaluated side-effects of lipid-lowering therapy.

Methods

Patients admitted with STEMI at Jena University Hospital were started on atorvastatin 80 mg and ezetimibe 10 mg on admission. Patients were followed for EAS/ESC LDL-C target achievement during follow-up.

Results

A total of 85 consecutive patients were enrolled in the study. On discharge, 32.9% achieved LDL-C targets on atorvastatin 80 mg and ezetimibe 10 mg. After 4–6 weeks, 80% of all patients on atorvastatin 80 mg and ezetimibe started at the index event were on ESC/EAS LDL-C targets. In 20%, combined lipid-lowering therapy was escalated with either bempedoic acid or PCSK9 inhibitors. All patients achieved LDL-C levels of or below 55 mg/dL during follow-up on triple lipid-lowering therapy. Combined lipid-lowering therapy was well-tolerated with rare side effects.

Conclusions

Early combination therapy with a high-intensity statin and ezetimibe and escalation of lipid-lowering therapy with either bempedoic acid or PCSK9 inhibitors gets potentially all patients with STEMI on recommended ESC/EAS LDL-C targets without significant side effects. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsST Elevation Myocardial InfarctionHydroxymethylglutaryl-CoA Reductase InhibitorsHumansProprotein Convertase 9AtorvastatinCholesterol, LDLPCSK9 InhibitorsProspective StudiesTreatment OutcomeEzetimibeDicarboxylic AcidsFatty Acids

Stichwörter der Autor:innen

LDL cholesterolLDL cholesterol target attainmentST-elevation myocardial infarctionSecondary prevention

Substanzen

Proprotein Convertase 9AtorvastatinAnticholesteremic AgentsCholesterol, LDLPCSK9 InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibe8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsFatty Acids

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
  • Division of Cardiology, Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. oliver.weingaertner@med.uni-jena.de.

Förderung

  • Universitätsklinikum Jena

Zitieren

APA

Makhmudova, U., Samadifar, B., Maloku, A., Haxhikadrija, P., Geiling, J. A., Römer, R., Lauer, B., Möbius-Winkler, S., Otto, S., Schulze, P. C., & Weingärtner, O. (2023). Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”). Clinical Research in Cardiology, 112(9), 1212-1219. https://doi.org/10.1007/s00392-022-02147-3

Vancouver

Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, Römer R, et al. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”). Clinical Research in Cardiology. 2023;112(9):1212-1219. doi:10.1007/s00392-022-02147-3

BibTeX
@article{Makhmudova2023,
  author = {Makhmudova, Umidakhon and Samadifar, Beasat and Maloku, Aurel and Haxhikadrija, Pellumb and Geiling, Jens-Arndt and Römer, Robert and Lauer, Bernward and Möbius-Winkler, Sven and Otto, Sylvia and Schulze, P Christian and Weingärtner, Oliver},
  title = {Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”)},
  journal = {Clinical Research in Cardiology},
  year = {2023},
  volume = {112},
  number = {9},
  pages = {1212--1219},
  doi = {10.1007/s00392-022-02147-3}
}
Kostenlos starten →